Is China Biologic Products Inc. (CBPO) A Good Stock To Buy? Centurium Capital Thinks So
We usually stay away from Chinese companies but we came across an interesting idea recently.
China Biologic Products Inc. (CBPO)
Market is closed
News
- First
- << Previous
- 11 - 20
- Next >>
Should You Follow Hedge Funds Into China Biologic Products Inc (CBPO)?
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database.
Should You Be Bullish on Tata Motors Limited (ADR) (TTM), China Biologic Products Inc (CBPO), & Two More?
At Insider Monkey, we think that an investor can outperform the market by following the aggregate moves of big hedge funds into the top picks they are bullish on.
Ariose Capital Generates Strong Returns from NetEase, Inc (ADR) (NTES) & Other Tech Stocks
Ariose Capital is a tech-focused fund managed by Yi Xin, which reported an equity portfolio worth $366.15 million as of the end of June.
Massive Insider Selling at Northrop Grumman (NOC) and Chinese Biotech, While Insider Buying Observed at 3 Other Companies
Peter Lynch, the former manager of the Magellan Fund at Fidelity Investments, once said that “Insiders might sell their shares for any number of reasons, but they buy them for only one: They think the...
China Biologic Products, Inc. (CBPO): Warburg Pincus Sells Shares to Underwriter
Warburg Pincus has just filed a Form 13D with the SEC, updating the regulatory body on the latest pertinent information related to its position in China Biologic Products Inc (NASDAQ:CBPO).
Is China Biologic Products Inc (CBPO) A Good Stock To Buy?
Out of thousands of stocks that are currently traded on the market, it might be really difficult to determine those that can really generate strong returns.
Should You Follow This Investor Into His Biotech Picks?
For the last year or so, many investors have been seeking profitable opportunities in the biotech sector, which has sent the shares of many stocks higher.
GL Partners Adds to Position in SciClone Pharmaceuticals; Reveals New Stake in China Biologic Products
GL Partners Capital Management has increased the holding of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) stock.
Hedge Funds Are Dumping Dendreon Corporation (DNDN)
To the average investor, there are tons of methods shareholders can use to monitor the equity markets. Two of the most under-the-radar are hedge fund and insider trading interest.
- First
- << Previous
- 11 - 20
- Next >>
Billionaire Hedge Funds
